The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse

NCT ID: NCT03436979

Last Updated: 2025-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to assess the long term safety, durability of clinical effectiveness and cost effectiveness of the NeuGuide™ system when used for vaginal colpopexy in the treatment of uterine prolapse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Prolapse Without Vaginal Wall Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects

Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.

NeuGuide™ System

Intervention Type DEVICE

The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeuGuide™ System

The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

transvaginal sacrospinous ligament fixation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient with POP-Q C point greater than (-) 1 cm.
2. Patients who have previously had a partial hysterectomy in which the cervix is intact may be included in this study.
3. Non-pregnant female (female of child bearing potential must have a negative pregnancy test).
4. Patient understands the nature and potential hazards of the procedure and provides written informed consent prior to any study specific assessments.
5. Patient is able to complete written questionnaires.
6. Patient is willing and able to comply with the specified study requirements and follow-up assessments, and can be contacted by telephone.

Exclusion Criteria

1. Known diagnosis of reproductive tract abnormalities.
2. Prior pelvic radiation therapy, any malignancy or active pelvic inflammatory disease.
3. Known history of severe Pelvic Inflammatory Disease (PID).
4. Prior total hysterectomy.
5. Prior pelvic prolapse surgery using synthetic mesh.
6. Pathological PAP in the past year.
7. Moderate or severe bacterial cervicitis.
8. Moderate or severe pelvic pain (\> 3 on VAS).
9. Severe morbid obesity (BMI \>45).
10. Temperature \> 38°C (oral or equivalent), sepsis, or active infection requiring IV anti-microbial treatment.
11. Significant cognitive impairment.
12. Active malignancy other than non-melanoma skin cancer.
13. Planned surgery (more than a minor one) in the next 30 days.
14. Patient has a known hypersensitivity to device materials (Nickel, suture material).
15. Moribund patient or patient with severe or deteriorating damage in critical body systems.
16. Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.
17. Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints.
Minimum Eligible Age

36 Years

Maximum Eligible Age

84 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pop Medical Solutions

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James C Leiter, M.D.

Role: STUDY_DIRECTOR

Avania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MedStar Health Research Institute

Washington D.C., District of Columbia, United States

Site Status

Holy Cross Hospital

Fort Lauderdale, Florida, United States

Site Status

Cleveland Clinic Florida

Weston, Florida, United States

Site Status

Mount Auburn Hospital

Cambridge, Massachusetts, United States

Site Status

Maimonides Medical Center

Brooklyn, New York, United States

Site Status

South Nassau Community Hospital Cancer Center

Valley Stream, New York, United States

Site Status

Cleveland Clinic Cleveland

Cleveland, Ohio, United States

Site Status

The Institute for Female Pelvic Medicine and Reconstructive Surgery

Allentown, Pennsylvania, United States

Site Status

Female Pelvic Health Center

Newtown, Pennsylvania, United States

Site Status

Walnut Hill OB/GYN Associates

Dallas, Texas, United States

Site Status

INOVA Women's Hospital

Falls Church, Virginia, United States

Site Status

Krankenhaus Waldfriede

Berlin-Zehlendorf, , Germany

Site Status

Isar Kliniken GmbH

München, , Germany

Site Status

St. Joseph Krankenhaus

Tempelhof, , Germany

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-CLP-0098

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.